Aerie Pharma appoints Richard Rubino as CFO

Biotechnology Company Aerie Pharmaceuticals has announced appointment of Richard J Rubino to the position of Chief Financial Officer.

Mr. Rubino has more than 30 years of financial, business and strategic planning experience, most recently with Medco Health Solutions, Inc.

Thomas van Haarlem, MD, President and Chief Executive Officer of Aerie Pharmaceuticals, said, “Mr. Rubino joins Aerie a very exciting time for the Company as we advance through Phase 2 clinical studies for 2 of our first-in-class products.” 

Mr. Rubino has extensive financial leadership and strategic planning experience in the healthcare industry brings an important skill set to the management team.

Mr. Haarlem also said, “Mr. Rubino has strong networks in the financial and payor communities will play an important role in the growth and development of Aerie. We are pleased to have someone of Rich’s caliber join our Executive Team.”  Mr. Rubino also said, “I am delighted to join the Aerie team and look forward to working with my colleagues in driving value through the rapid advancement of Aerie’s promising glaucoma pipeline. I feel privileged to join Aerie as we prepare for an important clinical data and am very excited about prospects for the future success of the company.”

Before joining Aerie, Mr. Rubino spent nearly 20 years at Medco, and held positions of increasing responsibility, including Chief Financial Officer and Chief Accounting Officer.

During his tenure at Medco, Mr. Rubino  was responsible for all aspects of finance, including accounting, treasury, strategic and financial planning, SEC reporting and investor relations. He has also served in various accounting and business alliance positions with International Business Machines Corporation.

Mr. Rubino was also a Senior Auditor at Price Waterhouse & Co. Mr. Rubino has also received his BS in Accounting from Manhattan College. He is also the board member and Treasurer of Northside Center for Child Development, a not-for-profit organization based in Harlem, New York.

Aerie Pharma is a privately held, clinical-stage biotechnology company involved in discovery and development of novel treatments for glaucoma. Currently, Aerie is evaluating AR-12286 in multiple Phase 2 clinical studies as a standalone therapy and in combination with a commercially available prostaglandin.